XML 72 R60.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Information (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Segment Reporting [Line Items]        
Number of operating segments | segment     1  
Number of reportable segments | segment     1  
Revenue:        
Total revenue $ 3,604 $ 0 $ 3,604 $ 0
Less:        
Cost of goods sold 93 0 93 0
Total research and development expenses 97,019 102,696 200,865 218,923
Total selling, general and administrative expenses 36,283 32,267 69,794 61,620
Intangible asset amortization 750 0 750 0
Total operating expenses 134,145 134,963 271,502 280,543
Loss from operations (130,541) (134,963) (267,898) (280,543)
Segment interest and other income, net 2,988 10,844 11,898 23,454
Therapeutics Segment        
Less:        
External research and development expenses - TV programs, including cost sharing 40,419 37,594 78,883 84,052
Other research and development expenses, including small molecule programs 16,494 24,847 40,048 54,347
Personnel related research and development expenses 40,106 40,255 81,934 80,524
Total research and development expenses 97,019 102,696 200,865 218,923
Personnel related selling, general and administrative expenses 22,921 20,115 45,485 38,853
Other selling, general and administrative expenses 13,362 12,152 24,309 22,767
Total selling, general and administrative expenses 36,283 32,267 69,794 61,620
Total operating expenses 134,145 134,963 271,502 280,543
Loss from operations (130,541) (134,963) (267,898) (280,543)
Segment interest and other income, net 2,988 10,844 11,898 23,454
Loss before income taxes $ (127,553) $ (124,119) $ (256,000) $ (257,089)